NOV 11, 2015 06:00 AM PST
Next-generation sequencing for BRCA1 and BRCA2 mutation testing
Presented at the Clinical Diagnostics and Research Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: CE
2 16 708

Speakers:
  • Global Product Manager, NGS, QIAGEN
    Biography
      Raed Samara, PhD is a Global Product Manager for NGS technologies at QIAGEN, with a focus on pre-analytics and targeted enrichment. Prior to joining QIAGEN, he was a postdoctoral fellow at the National Cancer Institute conducting research in the field of cancer immunology with emphasis on identifying strategies to boost the efficacy of cancer vaccines. He received his Ph.D. degree from Georgetown University in tumor biology.

    Abstract:
    Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other cancers.  Studying mutations along the entire length of these genes will bring us closer to winning the fight against cancer, so every base of BRCA1 and BRCA2 is important to your cancer research. QIAGEN recently launched the GeneRead DNAseq BRCA1/2 Targeted Panel covering 100% of the coding region and intron-exon junctions, enabling you to analyze every base of the BRCA1 and BRCA2 genes. This presentation will cover the development, experimental verification, NGS workflow, and data interpretation associated with the BRCA1/2 targeted DNA sequencing panel.

    Show Resources
    Loading Comments...